阻塞性睡眠呼吸暂停综合征患者血清Nesfatin-1水平变化及临床意义

Abstract
Figure/Table
References (23)
Related Citation (3)

Download: PDF (404 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the expression of serum Nesfatin-1 in patients with obstructive sleep apnea syndrome (OSAS) and its clinical significance. Methods Fifty patients with OSAS admitted to Yuebei People′s Hospital of Shaoguan City, ("our hospital" for short) from June 2016 to June 2017 were selected as OSAS group and divided into mild subgroup (10 cases), moderate subgroup (24 cases) and severe subgroup (16 cases) according to apnea hypopnea index (AHI). Another 30 healthy subjects visited the physical examination center of our hospital in the same period were selected as control group. Serum Nesfatin-1 level, Epworth sleepiness scale (ESS) score, AHI, minimum oxygen saturation (LSaO2) and maximum apnea time (Tmax) were compared between OSAS group and control group. Serum Nesfatin-1 level, ESS score, LSaO2 and Tmax in different subgroups of OSAS were observed. Pearson correlation analysis was used to analyze the correlation between ESS score, AHI, Tmax and LSaO2 and serum Nesfatin-1 level. Subject working characteristic curve (ROC) was used to evaluate the diagnostic efficacy of Nesfatin-1 in OSAS. Results Serum Nesfatin-1 level, ESS score and AHI in OSAS group were significantly higher than those in control group, LSaO2 in OSAS group was significantly lower than that in control group, and Tmax in OSAS group was significantly longer than that in control group (P < 0.05). Serum Nesfatin-1 level, ESS score and Tmax in mild, moderate and severe subgroups increased with the severity of the disease, while LSaO2 decreased with the severity of the disease (P < 0.05). ESS score, AHI and Tmax in OSAS group were positively correlated with serum Nesfatin-1 level (r = 0.711, 0.621, 0.357, all P < 0.05), and LSaO2 was negatively correlated with serum Nesfatin-1 (r = 0.477, P < 0.05). The sensitivity and specificity of serum Nesfatin-1 (≥ 4.8 μg/L) for diagnosis of OSAS were 81.52% and 76.17% respectively. Conclusion The level of serum Nesfatin-1 in OSAS patients is abnormally elevated, and the degree of elevation is related to the severity of the disease, which has guiding significance for clinical diagnosis and treatment.

Key words： Obstructive sleep apnea syndrome Apnea hypopnea index Nesfatin-1 Metabolic disturbance

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAI Wencan LI Tong LIU Yanming QIAN Chunyan CHEN Weijuan

Cite this article:

CAI Wencan LI Tong LIU Yanming QIAN Chunyan CHEN Weijuan. Changes and clinical significance of serum Nesfatin-1 level in patients with obstructive sleep apnea syndrome[J]. 中国医药导报, 2019, 16(28): 162-165.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I28/162

[1] 李文鹏.阻塞性睡眠呼吸暂停综合征与代谢综合征[J].中国循环杂志，2015，30（5）：511-512.
[2] 朱滢，周英.多导睡眠监测仪在老年阻塞性睡眠呼吸暂停综合征中的应用[J].中外医疗，2015，34（1）：60-61.
[3] 刘敏，李承红.血清visfatin水平对OSAHS严重程度的判断和诊断价值[J].临床肺科杂志，2018，23（3）：490-493.
[4] 张杨，郭洁，范崇盛.血压变异性及血清瘦素与阻塞性睡眠呼吸暂停低通气综合征的关系研究[J].实用预防医学，2018，25（6）：723-725.
[5] 秦小云.核组蛋白2/Nesfatin-1的研究新进展[J].广西医学，2014，36（11）：1602-1604.
[6] 中华医学会呼吸病学分会睡眠呼吸障碍学组.阻塞性睡眠呼吸暂停低通气综合征诊治指南（2011年修订版）[J].中华结核和呼吸杂志，2012，35（1）：162-165.
[7] 张莹，刘晖，叶红.Epworth嗜睡量表评估阻塞性睡眠呼吸暂停低通气综合征病情的价值[J].广西医学，2013，35（12）：1659-1660.
[8] 曹晓羽，涂红缨.阻塞性睡眠呼吸暂停低通气综合征发病机制研究进展[J].南昌大学学报：医学版，2014，54（6）：96-100.
[9] 袁亚芳，陈文宇，潘稚芬.阻塞性睡眠呼吸暂停低通气综合征并发充血性心力衰竭的机制研究进展[J].中国现代医生，2017，55（35）：165-168.
[10] 汪迎春，张玮玮，王磊，等.阻塞性睡眠呼吸暂停低通气综合征合并高血压患者皮质下觉醒反应特点分析[J].中国医药导报，2018，15（2）：46-49，66.
[11] 刘晨，刘阳，徐应军，等.瘦素、胰岛素生长因子-1与OSAHS关联性的研究[J].临床肺科杂志，2015，20（12）：2220-2222.
[12] 王高华，张楠，王惠玲，等.nesfatin-1的神经内分泌作用研究进展[J].中国临床研究，2018，31（2）：261-265.
[13] 徐海波，闫晓光，钟威.新诊断2型糖尿病患者血清Nesfatin-1、肿瘤坏死因子-α水平与胰岛素抵抗的相关性研究[J].中国糖尿病杂志，2017，25（1）：45-48.
[14] 张玥，曲艳，马浩越，等.中枢Nesfatin-1对脂肪组织UCP-1表达影响及机制[J].青岛大学医学院学报，2017， 53（6）：631-634，639.
[15] 欧阳晓平，顾扬，吴峰，等.阻塞性睡眠呼吸暂停低通气综合征合并2型糖尿病患者血清相关细胞因子变化的临床意义[J].疑难病杂志，2018，17（6）：567-571.
[16] 王书瑶，唐妮，齐锦雯，等.Nesfatin-1调节脂肪代谢的研究进展[J].生命科学，2018，30（5）：533-538.
[17] Nozawa S，Kimura T，Kurishima M，et al. Analyses of a satiety factor NUCB2/nesfatin-1：gene expressions and modulation by different dietary components in dogs [J]. J Vet Med Sci，2016，78（3）：411-417.
[18] Algul S，Ozkan Y，Ozcelik O. Serum nesfatin-1 levels in patients with different glucose tolerance levels [J]. Physiol Res，2016，65（6）：979-985.
[19] 谭丽艳，徐海波，谭丽萍，等.新诊断2型糖尿病患者血清nesfatin-1及apelin与胰岛素抵抗的关系研究[J].中国全科医学，2013，16（5）：493-495.
[20] 刘云涛，简磊，李建伟，等.糖代谢及胰岛素抵抗改善对2型糖尿病患者血清nesfatin-1水平的影响[J].重庆医学，2014，43（13）：1624-1626.
[21] 蒋书东，张兴旺，王登峰，等.Nesfatin-1/NUCB2在犬下丘脑-垂体-卵巢轴相关组织上表达与分布的研究[J].中国兽医科学，2017，47（11）：1461-1467.
[22] 张玮，王巧玲，逄明杰，等.下丘脑Nesfatin-1/NUCB2对糖尿病小鼠摄食的影响[J].现代生物医学进展，2015， 15（8）：1440-1443.
[23] 何悠，白桦，李荣杰.阻塞性睡眠呼吸暂停综合征患者血清摄食抑制因子1水平与不同病情程度评价指标之间相关性研究[J].临床肺科杂志，2017，22（12）：2204-2207.